Pamela Cohen

3.3k citations

31 papers · 2.6k indexed · 1 hit paper · h-index 21

Molecular Biology top 10%
Hematology top 1%
Immunology top 5%
Genetics top 2%
Oncology top 10%

Co-authors: Richard M. Stone Yanfeng Wang Stephen D. Nimer Ilene Galinsky Kevin J. Tracey M Shatsky Bertil Glader Michael P. Link
Topics: Chronic Myeloid Leukemia Treatments (10 papers)Acute Myeloid Leukemia Research (8 papers)Chronic Lymphocytic Leukemia Research (6 papers)
Cited by: Hematology Genetics Virology
Journals: The Journal of Experimental Medicine Journal of Clinical OncologySHILAP Revista de lepidopterología
Partner nations: United States United Kingdom Switzerland

In The Last Decade

Pamela Cohen

30 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

2004 528 citations Richard M. Stone, Ilene Galinsky et al. Blood profile →

Peers

Countries citing papers authored by Pamela Cohen

Since Specialization

Citations

This map shows the geographic impact of Pamela Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pamela Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pamela Cohen more than expected).

Fields of papers citing papers by Pamela Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pamela Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pamela Cohen. The network helps show where Pamela Cohen may publish in the future.

Co-authorship network of co-authors of Pamela Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Pamela Cohen. A scholar is included among the top collaborators of Pamela Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pamela Cohen. Pamela Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract CT032: A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies 2020 ·Cancer Research ·Antonio Jimeno,Shilpa Gupta,Ryan J. Sullivan,T. Khanh,Wallace Akerley,Ding Wang,Deanna Teoh,Kurt A. Schalper,Sima J. Zacharek,Jing Sun,Andressa S. Laino,Joshua P. Frederick,Honghong Zhou,(unknown),Stéphanie Pascarella,Lisa M. Johansen,Pamela Cohen,Robert Meehan,Todd M. Bauer	36
2	A phase 1, open-label, multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in subjects with resected solid tumors and in combination with pembrolizumab in subjects with unresectable solid tumors (Keynote-603). 2019 ·Journal of Global Oncology ·Howard A. Burris,Manish R. Patel,Daniel C. Cho,Jeffrey Clarke,Martin Gutierrez,Tal Zaks,Joshua P. Frederick,Kristen Hopson,(unknown),(unknown),Céline Robert-Tissot,Kristen Cowens,(unknown),Shan Zhong,Haiyu Zhou,Pamela Cohen,Karen Keating,Robert Meehan,Justin F. Gainor	20
3	Abstract 1796: SAR302503: A Jak2 inhibitor with antitumor activity in solid tumor models 2012 ·Cancer Research ·Rita Greco,(unknown),Fangxian Sun,(unknown),Qunyan Yu,Juliet Williams,Marion Dorsch,Pamela Cohen,Francisco Adrián	4
4	JAKARTA: A phase III, multicenter, randomized, double-blind, placebo-controlled, three-arm study of SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF with splenomegaly. 2012 ·Journal of Clinical Oncology ·Animesh Pardanani,Jörge E. Cortes,Francisco Cervantes,Claire Harrison,Francesco Passamonti,Claudia Lebedinsky,Frank Neumann,Pamela Cohen,Ayalew Tefferi	2
5	Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand ¹⁸F-AH111585 in Breast Cancer Patients 2008 ·Journal of Nuclear Medicine ·Laura Kenny,R. Charles Coombes,Inger Oulie,Kaiyumars Contractor,Matthew P. Miller,T J Spinks,Brian J. McParland,Pamela Cohen,Ai‐Min Hui,Carlo Palmieri,Safiye Osman,Matthias Glaser,David R. Turton,Adil Al‐Nahhas,Eric O. Aboagye	237
6	The Biodistribution and Radiation Dosimetry of the Arg-Gly-Asp Peptide ¹⁸F-AH111585 in Healthy Volunteers 2008 ·Journal of Nuclear Medicine ·Brian J. McParland,Matthew P. Miller,T J Spinks,Laura Kenny,Safiye Osman,Mandeep Khela,Eric O. Aboagye,R. Charles Coombes,Ai‐Min Hui,Pamela Cohen	55
7	Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors 2006 ·Blood ·Mark J. Levis,Patrick A. Brown,B. Douglas Smith,Adam Stine,(unknown),Richard M. Stone,(unknown),Ilene Galinsky,Frank Giles,Elihu H. Estey,Hagop M. Kantarjian,Pamela Cohen,Yanfeng Wang,Johannes Roesel,Judith E. Karp,Donald Small	164
8	Pharmacokinetic and Pharmacodynamic Studies of Lestaurtinib (CEP-701) and PKC-412: Cytotoxicity Is Often Dependent on Non-FLT3-Mediated Effects. 2005 ·Blood ·Mark J. Levis,Adam Stine,(unknown),Benjamin D. Smith,Judith E. Karp,Richard M. Stone,Elihu H. Estey,Frank Giles,Hagop M. Kantarjian,Pamela Cohen,Yanfeng Wang,Donald Small	11
9	Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain 2005 ·Blood ·Florian H. Heidel,(unknown),Frank Breitenbuecher,Daniel B. Lipka,Stefan Kasper,Melanie Thiede,Christian Brandts,Hubert Serve,Johannes Roesel,Francis J. Giles,Eric J. Feldman,Gerhard Ehninger,Gary J. Schiller,Stephen D. Nimer,Richard M. Stone,Yanfeng Wang,Thomas Kindler,Pamela Cohen,Christoph Huber,Thomas Fischer	211
10	Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Patients with AML. 2005 ·Blood ·Richard M. Stone,Thomas Fischer,Ronald Paquette,Gary J. Schiller,Charles A. Schiffer,Gerhard Ehninger,Jörge E. Cortes,Hagop M. Kantarjian,(unknown),Richard Yu,Lei Zhang,Pamela Cohen,Yanfeng Wang,Penny Phillips,Francis J. Giles	27
11	Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3 2004 ·Clinical Cancer Research ·Purva Bali,Prince George,Pamela Cohen,Jianguo Tao,Fei Guo,Celia Sigua,Anasuya Vishvanath,Anna Scuto,Srinivas Annavarapu,Warren Fiskus,Lynn C. Moscinski,Peter Atadja,Kapil N. Bhalla	114
12	Cotreatment with 17-Allylamino-Demethoxygeldanamycin and FLT-3 Kinase Inhibitor PKC412 Is Highly Effective against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3 2004 ·Cancer Research ·Prince George,Purva Bali,Pamela Cohen,Jianguo Tao,Fei Guo,Celia Sigua,Anasuya Vishvanath,Warren Fiskus,Anna Scuto,Srinivas Annavarapu,Lynn C. Moscinski,Kapil N. Bhalla	113
13	On-Demand Education to Meet Marine Industry Professional Development Needs 1999 ·Journal of Ship Production ·(unknown),(unknown),(unknown),Pamela Cohen	1
14	Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans 1997 ·Critical Care Medicine ·Leslie T. Aiuto,Stephen Barone,Pamela Cohen,Robert A. Boxer	109
15	Spermine Inhibits Proinflammatory Cytokine Synthesis in Human Mononuclear Cells: A Counterregulatory Mechanism that Restrains the Immune Response 1997 ·The Journal of Experimental Medicine ·Minghuang Zhang,Theresa Caragine,Haichao Wang,Pamela Cohen,Galina I. Botchkina,Kuniyasu Soda,Marina Bianchi,Peter Ulrich,Anthony Cerami,Barbara Sherry,Kevin J. Tracey	269
16	Targeted Suppression of Cytokine Production in Monocytes but Not in T Lymphocytes by a Tetravalent Guanylhydrazone (CNI‐1493) 1997 ·The Journal of Infectious Diseases ·Lars Björk,Kevin J. Tracey,Peter Ulrich,Marina Bianchi,Pamela Cohen,(unknown),Thomas E. Fehniger,Jan Andersson	30
17	The Critical Role of p38 MAP Kinase in T Cell HIV-1 Replication 1997 ·Molecular Medicine ·Pamela Cohen,Helena Schmidtmayerova,Jameel Dennis,Larisa Dubrovsky,Barbara Sherry,Haichao Wang,Michael Bukrinsky,Kevin J. Tracey	95
18	Induction of transforming growth factor beta 1 and its receptors during all-trans-retinoic acid (RA) treatment of RA-responsive human neuroblastoma cell lines. 1995 ·PubMed ·Pamela Cohen,John J. Letterio,Carlo Gaetano,(unknown),Kazue Matsumoto,Michael B. Sporn,Carol J. Thiele	58
19	Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors. 1990 ·PubMed ·Pamela Cohen,Mark J. Cooper,Lee J. Helman,Carol J. Thiele,Robert C. Seeger,Mark A. Israel	39
20	Analysis of nerve growth factor receptor expression in human neuroblastoma and neuroepithelioma cell lines. 1989 ·PubMed ·David L. Baker,Usha R. Reddy,David Pleasure,(unknown),Audrey E. Evans,Pamela Cohen,Alonzo H. Ross	57

About Pamela Cohen

Pamela Cohen is a scholar working on Hematology, Genetics and Immunology, having authored 31 papers that have together received 2.6k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (10 papers), Acute Myeloid Leukemia Research (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). The work is most often cited by research in Hematology (990 citations), Genetics (449 citations) and Virology (186 citations). Pamela Cohen has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include Richard M. Stone, Yanfeng Wang, Stephen D. Nimer, Ilene Galinsky, Kevin J. Tracey, M Shatsky, Bertil Glader, Michael P. Link, Stephen D. Smith and Daniel J. DeAngelo. Their work appears in journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact